Sep 2026· Journal of Alzheimer's Disease· Vol 114, pp. 241 - 253· 0 citations· 73 references
Medicine
TL;DR
Plasma p-tau217 is established as a first-choice biomarker for the early detection of AD pathology in specialized clinical settings, displaying excellent diagnostic accuracy and minimal site-related variability.
BACKGROUND
Implementation of disease-modifying anti-amyloid therapies for Alzheimer's disease remains constrained by the cost and procedural burden of positron emission tomography and cerebrospinal fluid testing. This review evaluates blood-based biomarkers in therapeutic pathways.
METHODS
PubMed/MEDLINE and Embase w...
Plasma biomarkers offer a transformative, non-invasive approach to early AD diagnosis and primary care triage, reducing reliance on CSF and PET scans and overcoming demographic and methodological limitations is essential for their widespread clinical adoption.
Małgorzata Witaszczyk, Alicja Sołtan, Natalia Wiktorzak et al.· International Journal of Inn...· 0 citations
Early and accurate diagnosis of Alzheimer’s disease (AD) is essential because disease modifying anti amyloid therapies are indicated for early symptomatic patients and require biomarker confirmation of amyloid pathology. Cerebrospinal fluid (CSF) biomarkers play a key clinical role, with the Aß42/Aß40 ratio showi...
N. Bacarov, C. Resende, Thais Dini et al.· Clinical Chemistry· 0 citations
Findings support the application of plasma AD biomarkers in the African context and the relevance of further AD biomarker research in diverse populations.
T. Akinyemi, I. Pola, K. Tan et al.· npj Dementia· 1 citation
BACKGROUND
Alzheimer's disease (AD) poses a growing global health challenge, highlighting the urgent need for reliable and minimally invasive diagnostic tools. This study aimed to develop and comprehensively validate an automated chemiluminescence immunoassay (CLIA) for the simultaneous quantification of six core plasm...
Xi-Meng Chen, Wen-Can Jiang, Li-Juan Wang et al.· Clinica chimica acta; intern...· 0 citations
BACKGROUND
Demonstrating the specificity of plasma biomarkers to AD-related neurodegeneration would add support to their prognostic and diagnostic clinical use.
METHOD
Participants from the Baltimore Longitudinal Study of Aging were cognitively unimpaired at the time of their plasma Aβ42/Aβ40, GFAP, NfL (Quanterix Ne...
Murat Bilgel, Ishaan Shah, Jasmine M. Cooper et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.